Pharmaceutical Care Process Development in the Diabetes Patients at Kantharalak Hospital
Thinyarat Prasannit1*, Sukhonthiya Amornrojwarrawut1

Introduction: Pharmacy department aims to improve the quality of care for patients with diabetes by using pharmaceutical care. Due to the large number of patients and many procedures involved in real practice, complicated issues in pharmaceutical care have been arising. Pharmaceutical care cannot be covered to all patients completely so as the adequate services provided by the pharmacist. To solve the problems, we modify the process of data collection and expand the collaboration between pharmacy department and other healthcare disciplined teams. The objective of this research is to study the impact of pharmaceutical care in patients with type 2 diabetes which possess high Fasting Blood Sugar level (FBS) in respect of workload, self-care behaviors and FBS control.

Materials and Method: Descriptive prospective analysis. Inclusion criterion were patients who have continued to have FBS level of ≥200 mg/dl at least 2 consecutive times, have stable blood pressure, and patients who visited the Diabetic Care Unit between February and June 2013. Provide pharmaceutical care by two pharmacists to searching for specific problems, to educating and expanding to teams. The patients were monitoring followed up every 35 days for 3 times.

Results: Mean time for pharmaceutical care was 6.33 min (5-14 min). The pharmaceutical care was provided in 185 patients from 379 (44.8%), 127 patients were treated by the behavior change method (67.8%). The study found that the problems were ranging from No exercise (88.1%), No diet control (77.3%), and inappropriate medicine use (6.5%), forgot to take medicine (6.5%), drug default and/or loss of follow up (6.5%) and lastly herb or food supplement use (3.2%). In the first follow-up the patients were found to have improved FBS of ≥150 mg/dl in 60 patients (33.4%). At the end of study, 70 patients (38.0%) had FBS of ≥ 200 mg/dl, 20 patients (15.7%) whose treated by behavior change method achieved normal targetted FBS level (70-130 mg/dl). In total 26 patients (14.1%) achieved targeted FBS level.

Conclusion: After modifying the processes of pharmaceutical care, pharmacy department can achieve 48.6% coverage of the pharmaceutical care. The diabetes patients improved their FBS level to 14.1%. However Hba1c should be monitored 1 times per year and other variables such as the relationship of proper medication prescribing or insulin resistance that leads to treatment outcome, these variables would be important to study further.

Keywords: Diabetes Care, Pharmaceutical Care

Pharmacokinetic Study and Therapeutic Drug Monitoring of Vancomycin in End Stage Renal Disease Patients
Teerapon Bootprom1, Weerapong Thumchotang1, Denpong Patanasethanon1, Aporanee Chaiyakum1, Siriluk Jaisue1, Suda Vannaprasaht2

Introduction: Vancomycin, a tricyclic glycopeptides antimicrobial, usually use in treatment of serious gram positive bacterial infections has narrow therapeutic index. Presently, resistant microorganisms to vancomycin had been gradually reported, therapeutic drug monitoring (TDM) of vancomycin should be performed during treatment. According to vancomycin excretion is predominantly by glomerular filtration, the data of pharmacokinetic parameters in renal insufficient patient is necessary for prevention of adverse drug reaction and effective dosage regimen.

Objectives: to study pharmacokinetic parameters of vancomycin and design the appropriate plan for TDM in end stage renal disease (ESRD) patients. Method: Retrospective study of the serum concentration of vancomycin data after receiving the first dose in patients with ESRD was performed. Then the calculated pharmacokinetic parameters from short-infusion model were used to predict the vancomycin concentrations in various times after administration to evaluate and design the appropriate plan for TDM. Results: The data of serum vancomycin concentrations from 123 ESRD patients whom received vancomycin 1 g i.v. drip in 2 hr q 96 hr at first dose were collected. The calculated pharmacokinetics parameters of vancomycin; volume of distribution, elimination rate constant, clearance, and elimination half-life were 7.21±36.57L, 0.003 ± 0.025 hr⁻¹, 0.40±0.14 L/hr, 71.76     ±32.39  hr, respectively. In addition, at 24 hr post dose, there were 52.85% and 16.26% of patients had subtherapeutic concentration of 15-20 and 10-15mg/L, respectively. Conclusion: At 24 hr after the first dose, TDM of vancomycin should be performed for designing and optimization of dosage regimen in individualized ESRD patients.

Keywords: Vancomycin, End Stage Renal Disease, Pharmacokinetics, Therapeutic Drug Monitoring

1Faculty of Pharmaceutical Sciences, Khon Kaen University.
2Faculty of Medicines, Khon Kaen University
*Corresponding author: Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand 40002 Tel/Fax 043-202378-9 e-mail: denpat@kku.ac.th